Get the Stockscreener App
4.8511
10.42%
-0.5689
Lexeo Therapeutics Inc stock is traded at $4.8511, with a volume of 591.56K.
It is down -10.42% in the last 24 hours and down -33.77% over the past month.
Lexeo Therapeutics Inc is a a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Its pipeline consists of candidates targeting patient populations that place significant burden on society and are most amenable to their genetic medicine approach. The Company is focused on preclinical and clinical stage gene therapies, and specifically on hereditary and acquired diseases of high unmet need which is their only business segment.
See More
Previous Close:
$5.42
Open:
$5.33
24h Volume:
591.56K
Relative Volume:
1.75
Market Cap:
$179.28M
Revenue:
-
Net Income/Loss:
$-86.60M
P/E Ratio:
-1.7127
EPS:
-2.8324
Net Cash Flow:
$-67.37M
1W Performance:
-10.59%
1M Performance:
-33.77%
6M Performance:
-58.58%
1Y Performance:
-71.44%
1-Day Range:
$4.74
$5.54
1-Week Range:
$4.74
$6.04
52-Week Range:
$4.67
$19.50
Lexeo Therapeutics Inc Stock (LXEO) Company Profile
Name
Lexeo Therapeutics Inc
Sector
Industry
Phone
(212) 547-9879
Address
345 PARK AVENUE SOUTH, NEW YORK
Compare LXEO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LXEO
Lexeo Therapeutics Inc
|
4.855 | 179.28M | 0 | -86.60M | -67.37M | -2.8324 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.30 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.08 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
653.05 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.28 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.71 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Lexeo Therapeutics Inc Stock (LXEO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-13-24 | Initiated | Robert W. Baird | Outperform |
| Jun-06-24 | Initiated | H.C. Wainwright | Buy |
| Nov-28-23 | Initiated | Chardan Capital Markets | Buy |
| Nov-28-23 | Initiated | JP Morgan | Overweight |
| Nov-28-23 | Initiated | Leerink Partners | Outperform |
| Nov-28-23 | Initiated | RBC Capital Mkts | Outperform |
| Nov-28-23 | Initiated | Stifel | Buy |
View All
Lexeo Therapeutics Inc Stock (LXEO) Latest News
BlackRock, Inc. Expands Holdings with Lexeo Therapeutics Inc. Ac - GuruFocus.com
JPMorgan Chase & Co. Boosts Holdings in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World
(LXEO) Trading Advice - Stock Traders Daily
Lexeo stock touches 52-week low at $4.76 amid market challenges - MSN
Leerink Partnrs Has Positive Outlook of LXEO FY2026 Earnings - Defense World
FY2026 EPS Estimate for Lexeo Therapeutics Raised by Analyst - MarketBeat
Lexeo Therapeutics’ (LXEO) Outperform Rating Reiterated at Royal Bank of Canada - Defense World
Royal Bank of Canada Reiterates Outperform Rating for Lexeo Therapeutics (NASDAQ:LXEO) - MarketBeat
Barclays PLC Acquires 31,057 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives $23.80 Consensus Target Price from Analysts - MarketBeat
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Lexeo stock plunges to 52-week low, hits $5.75 amid market challenges - Investing.com Nigeria
How to Take Advantage of moves in (LXEO) - Stock Traders Daily
Jane Street Group LLC Buys 8,918 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World
Solid Biosciences stock jumps 11% post-market on FDA update - MSN
Lexeo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Lexeo Therapeutics CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Geode Capital Management LLC Increases Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World
Geode Capital Management LLC Acquires 256,635 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - MarketBeat
Barclays PLC Buys 31,057 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Stake Raised by State Street Corp - Defense World
When (LXEO) Moves Investors should Listen - Stock Traders Daily
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
BNP Paribas Financial Markets Increases Stake in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World
Charles Schwab Investment Management Inc. Buys 33,013 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World
Lexeo Therapeutics appoints new CFO amid growth - Investing.com
Lexeo Therapeutics Appoints Dr. Kyle Rasbach as CFO - TipRanks
Lexeo Therapeutics Names Kyle Rasbach Chief Financial Officer - MarketWatch
Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer - The Manila Times
Lexeo Therapeutics Appoints Investment Veteran & Life Sciences Expert Dr. Rasbach as New CFO - StockTitan
Lexeo Therapeutics, Inc. Appoints Kyle Rasbach as Chief Financial Officer - Marketscreener.com
Lexeo Therapeutics' SWOT analysis: gene therapy stock's potential and pitfalls - Investing.com
Lexeo Therapeutics' SWOT analysis: gene therapy stock poised for catalysts By Investing.com - Investing.com Nigeria
Lexeo Therapeutics' SWOT analysis: gene therapy stock poised for catalysts - Investing.com India
Frazier Life Sciences Management L.P. Invests $11.31 Million in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - MarketBeat
Point72 Asset Management L.P. Makes New $3.35 Million Investment in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - MarketBeat
Janus Henderson Group PLC Purchases 599,203 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - MarketBeat
RA Capital Management L.P. Reduces Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - MarketBeat
LXEOLexeo Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Verition Fund Management LLC Boosts Stake in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - MarketBeat
Eventide Asset Management LLC Has $16.78 Million Holdings in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - MarketBeat
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Shares Sold by Braidwell LP - MarketBeat
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Insider Spends US$105k Buying More Shares In Lexeo Therapeutics - Simply Wall St
Lexeo Therapeutics Inc Stock (LXEO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lexeo Therapeutics Inc Stock (LXEO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Townsend Richard Nolan | Chief Executive Officer |
Dec 10 '24 |
Sale |
8.20 |
2,500 |
20,491 |
120,695 |
0.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):